BLOG POSTS AND TWITTER ACTIVITY


How blockchain healthcare is advancing the management of medical records http://ow.ly/BDLm30kPvcl via @rosedefremery #Blockchain #Healthcare #BlockchainHealthcare #Technology


Seeking solutions for increased #Compliance to treatment, improved access to #clinicaltrials, ways to merge #data. Got an idea? Have a solution that would transfer to #healthcare #lifesciences Compete in the Inject Tech Challenge https://www.biocrossroads.com/summit/injecttech/ https://t.co/ePent3Mcjq


Review of the outstanding presentation by @5uggy @sveckert @tillkrause and deep dive into the underbelly of predatory publishing and its far-reaching damage to the fabric of #science http://incrementalhealthcare.com/defending-science/ https://t.co/87uU75VShR


MyIRE is pleased to announce the launch of the MYR token pre-sale! The MYR token will enhance our platform’s ability to facilitate reproducible clinical research at a fraction of the cost of existing tools. Visit https://myire.com to participate! http://myire.com


Are you a woman pursuing research in science, technology, engineering, math, manufacturing or design? #JNJ is supporting #WomeninSTEM through a $150k award. The #WiSTEM2D Scholars Award application period will be open from 9/4–25, 2018. Learn more: https://goo.gl/kTRZUD https://t.co/Abrg6TI9yg


FDA launches a new Medication Guide database with new and improved features including active ingredient and brand name search, improved mobile device usability, & more! Check out here: https://go.usa.gov/xUAwF. https://t.co/dT6pIOAohk


@CMSGov Beth Conner tells us role of standardized data element capture to support interoperability, person-centered care and care planning, reducing #providerburden #DEL #interopForum @ONC_HealthIT


DYK #BlueButton 2.0 from @CMSgov is an #API that contains four years of Medicare Part A, B and D data for 53 million Medicare beneficiaries? #InteropForum https://t.co/BsryxyEO3X


PubMed Health will be discontinued October 31, 2018. But don't worry! The content (consumer health resources, systematic reviews, & comparative effectiveness research) will still be available at NLM. More info: http://bit.ly/2LW5xI6 #consumerhealth #systematicreview #CER https://t.co/K0TJFw3g3f


Your private medical data  are bought & sold in a marketplace valued in the billions. Even though the data came from your body, it doesn’t belong to you. @hu_manityco wants to replace this "data feudalism" with a more transparently capitalist relationship. https://buff.ly/2O8q5KW


New precisionFDA CDRH Infectious Disease NGS Diagnostics Biothreat Challenge starts today! Learn more at https://precision.fda.gov/challenges #FDABiothreatChallenge #NGS https://t.co/8XkdeTzlQq


FDA just published a list of surrogate endpoints which were the basis of approval or licensure of a drug or biologic product under accelerated or traditional approval https://bit.ly/2uPQLJ3. It provides useful information for drug developers on endpoints that may be considered. https://t.co/o74ZJzGoUg


.@NIHClinicalCntr has made a dataset of 32,000 CT images publicly available to help the scientific community improve detection accuracy of lesions. https://go.usa.gov/xUyfb https://t.co/7Mt7gzUDUU


#Beta tests for #MYR #token #presale went well. Accepting #USD #ETH #BTC. Requires AML, KYC, AI checks. Keep a look out for the #public #launch of the #presale shortly. Reach out to support@myire.com with any questions. #MyIRE #ReproducibleResearch #Blockchain #Crypto


@LesslLessl, Head of Corporate Innovation and R&D at Bayer AG, opens her speech with the words: ‘no innovation without collaboration’. What do you think? We agree on that! #science4impact #innovation #collaboration #AlumniDay https://t.co/Y7jrCiaTov


MyIRE was featured at Chain Reaction Blockchain Healthcare Summit, the first “evidence-based” blockchain healthcare summit. We participated in an interactive panel entitled Blockchain for Increased Trust in Clinical Trials.



My Integrated Research Environment (“MyIRE”) is a novel technology that we believe will increase clinical trial throughput and simultaneously increase their process and data integrity. As a comprehensive scientific software platform, MyIRE is designed to provide end-to-end support for clinical trials supported by blockchain-enabled features to facilitate data integrity and transferability, as well as to confirm consistency of protocol execution, and therefore generate improved study results through reproducibility. We present a disruptive economic model showing how we anticipate this result will be achieved for a fraction of the cost associated with, and resulting from, using existing tools. We believe this combination of a novel technology and the proposed economic model provides a compelling case for a new cryptocurrency token.



Our four-node proof of concept infrastructure consists of Network, Infrastructure, Compute, and Storage nodes. We used non-specialty, commercially available hardware with machines consuming 50% maximum capacity in terms of processing, RAM, and storage. Power optimization was not taken into account. Rather, the potential for maximal participation was targeted by optimizing for mass commercial availability. Control plane segregation, separation of concerns, and principles of least privilege were three factors also considered in our design.



MyIRE presented a seminar entitled “Building Blocks of Rapidly Iterable, Reproducible Clinical Trials” to the CBER HIVE Team. **Abstract:** Easy to use tools are revolutionizing medical innovation, but the "telephone game of research software tools" has implications on participant privacy and scientific integrity. Increasing expectations for privacy and integrity can be achieved by harnessing the power of existing open technologies. MyIRE will present strategies for successful adoption of open technologies and case studies of building blocks for rapidly iterable, reproducible clinical trials.



Internal validity and end-user acceptance of individual modules was tested via deployment across multiple organizations. We put into place legally binding contracts for decentralization of those modules with differential privacy restrictions that may be regulated. Module provenance and history were stored with the capacity for each organization to verify integrity. Modules were stored separately from data owned by each organization, so data integrity and module integrity can be verified independently.



MyIRE presented a case study of blockchain technology combined with easy to use tools and its impact on research integrity. We also demonstrated how this approach empowers doctors to participate in research as part of their daily practice.



Internal validity and end-user acceptance of individual modules was tested via deployment across multiple organizations. We put into place legally binding contracts for decentralization of those modules with differential privacy restrictions that may be regulated. Module provenance and history were stored with the capacity for each organization to verify integrity. Modules were stored separately from data owned by each organization, so data integrity and module integrity can be verified independently.



Modules comprising the process of creating a hypothesis, testing it, and publishing the results were composed into projects. Multiple projects were run through the system. The results of one of the projects are ready to submit for peer review with the expectation that the results will be published in a journal with a reference to MyIRE. That project will be repeatable, in the manner described above, by anyone and anywhere -- thereby minimizing instrumental bias. The project was forked to a different node of the same specification. Alterations were made to individual data collection elements within the forked study. Interfaces remained interoperable and the project was auto-documenting. Underlying data was not transferred between machines.



Mark Graves, Jr. is one of our founders, and the developer of the MyIRE platform. Mr. Graves has served as our chief executive officer, president and chief technical officer since the company was founded in December 2015. Mr.Graves began a clinical research career while still a teenager and has years of experience designing and delivering clinical and preclinical trials. He earned a bachelor’s degree from Northwestern University and attended Northwestern University’s Feinberg School of Medicine for two years. Mr. Graves brings to the company unique perspective and insights regarding the strategic and operational opportunities and challenges, economic and industry trends, and competitive and financial positioning of our business. Mark Graves Sr., MD is one of our founders. Dr. Graves is an internist, and is affiliated with Deaconess Hospital in Evansville, IN. He received his medical degree from University of Pittsburgh School of Medicine and has been in practice for more than 20 years. Dr. Graves is a clinical investigator and has worked on more than 100 clinical trials of medications and devices. Dr. Graves has experience in designing trials, writing informed consents, writing protocols, interacting with the IRB, following regulations, and managing and analyzing trial data. Dr. Graves brings to the company significant operational, regulatory, and financial experience as a physician and clinical investigator. Gregory Folz, CCRP is one of our founders. Mr. Folz is the Administrative Director of Research for the Deaconess Research Institute, where he has overseen the conduct of more than 800 clinical trials. Mr. Folz was recently recognized as “2018 Top 20 Innovators” in the clinical research industry; and is the recipient of the 2016 SCRS Site Tank Award for Innovation, and a finalist for the Society for Clinical Research Site’s 2015 Innovation Award for patient recruitment. Mr. Folz serves as a national consultant and speaker on the development of clinical research operations and business structures and has assisted more than a dozen US hospital systems, networks, and physician groups on the strategic growth of their clinical research initiatives. Mr.Folz brings a wealth of clinical trial experience and relationships to the company.



MyIRE, Inc. is a Delaware C Corp.


Subscribe. and stay informed.